ArticleThe patient2021
Measurement Properties of the EQ-5D-5L and EQ-5D-3L in Six Commonly Diagnosed Cancers.
Article in The patient, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 55 citations in OpenAlex.
- Digital Self-Management of Symptoms and Quality of Life for Patients With Advanced Cancer: A Randomized Clinical Trial.JAMA network open · 2026Trial
- Associations between perceived neighborhood environment and physical activity among breast cancer patients engaged in a physical activity program concomitant to cancer treatment: cross-sectional and longitudinal analyses in the DISCO trial (DiscoSpace).The international journal of behavioral nutrition and physical activity · 2026Trial
- Impacts of the preceding cancer-specific health-related quality of life instruments on the responses to the subsequent EQ-5D-5L.Health and quality of life outcomes · 2023Trial
- Complex intervention including pain science education and patient-led goal setting-based self-management strategies for management of aromatase inhibitor-induced musculoskeletal symptoms: a single-arm feasibility and pilot study.Journal of cancer survivorship : research and practice · 2026Article
- Cancer-specific or generic preference-based measures in oncology? A validity comparison across six commonly diagnosed cancers.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2026Article
- Presenteeism in working-age breast cancer survivors 1-5 years after surgery: relative contributions of treatment-related symptoms and modifiable factors.Breast cancer (Tokyo, Japan) · 2026Article
- Article
- Associations between financial toxicity, health-related quality of life, and well-being in Indonesian patients with breast cancer.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2025Article
- Patient Experiences Regarding Feasibility of Implementing Real-World EQ-5D Collection at an Oncology Centre in Ontario, Canada.Current oncology (Toronto, Ont.) · 2025Article
- Cost-effectiveness of low-dose CT screening for non-smokers with a first-degree relative history of lung cancer.BMC public health · 2025Article
- Assessment of Health-Related Quality of Life in Thai Endometrial Cancer Patients: A Comparative Analysis Using EQ5D Utility Scores Across States.Cancer reports (Hoboken, N.J.) · 2025Article
- The COVID-19 pandemic experience for patients with central nervous system tumors: Differences in patient-reported outcomes and practice recommendations.Neuro-oncology practice · 2025Article
- Assessing the reliability and responsiveness of the SF-6Dv2 and comparing its validity to the EQ-5D-5L among colorectal cancer patients in China.Frontiers in oncology · 2025Article
- The EORTC QLU-C10D is a valid cancer-specific preference-based measure for cost-utility and health technology assessment in the Netherlands.The European journal of health economics : HEPAC : health economics in prevention and care · 2024Article
- Assessing the reliability of a novel cancer-specific multi-attribute utility instrument (FACT-8D) and comparing its validity to EQ-5D-5L in colorectal cancer patients.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2024Article
- Measurement properties of the EQ-5D-3L, EQ-5D-5L, and SF-6Dv2 in patients with late-onset Pompe disease.The European journal of health economics : HEPAC : health economics in prevention and care · 2024Article
- A comparison of measurement properties between EORTC QLU-C10D and FACT-8D in patients with hematological malignances.Health economics review · 2024Article
- Cancer-Specific Health Utilities: Evaluation of Core Measurement Properties of the EORTC QLU-C10D in Lung Cancer Patients-Data from Four Multicentre LUX-Lung Trials, Applying Six Country Tariffs.PharmacoEconomics - open · 2024Article
- Article
- Risk-based lung cancer screening in heavy smokers: a benefit-harm and cost-effectiveness modeling study.BMC medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to compare the measurement properties of the EQ-5D-3L (3L) and EQ-5D-5L (5L) in cancer patients.
methodsA consecutive sample of inpatients with lung, breast, colorectal, liver, gastric, or thyroid cancer were interviewed using the 3L, 5L, and Functional Assessment of Cancer Therapy-General (FACT-G) questionnaires, and a subgroup was invited to complete the 3L and 5L again. Kappa and intraclass correlation coefficient were used to assess test-retest reliability, and Spearman's correlation between the EQ-5D and FACT-G was evaluated to assess convergent validity. Comparison of subgroups defined using Eastern Cooperative Oncology Group status and cancer stage were performed to assess known-group validity and discriminatory power using the F-statistic and area under the receiver-operating characteristics curve. All analyses were also performed for each subgroup of cancer patients.
resultsA total of 416 cancer patients completed the baseline questionnaire and 90 patients also completed the follow-up survey after 2 days. Ceiling effects were smaller in 5L (10.1%) than in 3L (17.8%). The test-retest reliability and convergent validity of the 5L were slightly better than those of the 3L. Both the 3L and 5L showed known-group validity; however, the 5L index showed better discriminatory power. Similar trends were found in the six types of cancers.
conclusionIn general, 5L appears to have better measurement properties than 3L for measuring the health-related quality of life of cancer patients. While both the 3L and 5L are suitable, 5L should be preferable to 3L for use in cancer outcomes research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.